TKTae-Hyung Kim

Tae-Hyung Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tae-Hyung Kim has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Review of systemic therapy in HCC with an approach to response assessment in clinical practice

    by Kevin A. Zand, Tae-Hyung Kim, Reetu Mukherji, Mohammed Ismail, Maria El Homsi, Amir Imanzadeh, Amita Kamath, Charanjeet Singh, Joseph H. Yacoub

    Systemic therapy for hepatocellular carcinoma (HCC) has undergone rapid transformation over the past decade, significantly expanding treatment options and improving survival for patients with advanced disease. Guided by the Barcelona Clinic Liver Cancer staging system, systemic therapy is primarily indicated for advanced-stage HCC and select intermediate-stage cases with preserved liver function. Immune checkpoint inhibitor-based combination regimens have redefined first-line therapy, demonstrating substantial improvements in overall survival and response rates. As systemic and locoregional treatments increasingly converge, radiologists are encountering more complex imaging scenarios requiring nuanced interpretation. Assessment of treatment response in HCC relies on integration of imaging findings, biomarkers, and clinical parameters. Although Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 remains the primary response assessment method in clinical trials, its size-based criteria may not fully capture biologic response in HCC, where therapy can induce necrosis or decreased vascularity without substantial tumor shrinkage. Modified RECIST (mRECIST), which evaluates viable enhancing tumor, may better reflect treatment effect in certain contexts; however, higher response rates by mRECIST have not consistently translated into improved overall survival. Atypical response patterns such as pseudoprogression and hyperprogression may further complicate evaluation in the immunotherapy era but remain uncommon in HCC. Emerging evidence suggests that combining systemic therapy with locoregional therapies such as transarterial chemoembolization, transarterial radioembolization, and stereotactic body radiation therapy may improve disease control and survival in selected patients, further increasing imaging complexity. In routine clinical practice, radiology reports should emphasize global disease burden assessment, “the forest, not the trees,” while clearly describing mixed responses, tumor-in-vein, and extrahepatic disease. In cases of temporally overlapping systemic and locoregional therapies, a compartmentalized approach integrating RECIST or mRECIST principles with LI-RADS treatment response algorithm for recently treated lesions, “the forest and the trees,” is recommended to support multidisciplinary decision-making. Advanced imaging techniques including perfusion imaging, radiomics, and artificial intelligence-based modeling offer promising tools for earlier and more precise response assessment but remain largely investigational. As therapeutic paradigms continue to evolve, radiologists play a central role in guiding management decisions. A comprehensive, multidisciplinary approach that integrates imaging interpretation with clinical context and treatment history is essential to accurately assess response and optimize care in patients with HCC receiving systemic therapy.


  • Radiomics in Hepatology

    by Tae-Hyung Kim, Richard Kinh Gian Do, Oguz Akin, Lawrence H. Schwartz

  • CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort

    by Wyanne Law, Junting Zheng, Tae-Hyung Kim, Natally Horvat, James J. Harding, Carlie Sigel, Mustafa Erdem Arslan, Alice Wei, Richard K. Do, Victoria Chernyak

    Objectives Various mutations in hepatocellular carcinoma (HCC) carry prognostic implications. The objective of this study is to assess CT and MRI imaging features associated with Catenin Beta-1 (CTNNB1) mutation in HCC. Methods This retrospective, IRB- approved multi-reader, single-center study included treatment-naive, pathologic-proven HCC that underwent contrast-enhanced CT, MRI or both, with subsequent targeted tumor sequencing test. Preoperative CT and MRI were reviewed for the Liver Imaging Reporting and Data System (LI-RADS, LR) features and prognostic imaging features. Fisher’s exact test and multiple testing adjustment were used to assess the association of imaging features and CTNNB1 mutation status. Results Of the 160 HCCs included (median age 69 [IQR: 62, 75], 125 men), 58 (36%) had CTNNB1 mutation. Compared to wildtype, CTNNB1-mutated HCCs were more likely to be present as solitary lesion (CT: 26/43[60%] vs. 31/80 [40%], p = 0.024), have mosaic appearance (MRI: 9/34[26%] vs. 3/68[4.4%], p = 0.002), blood products in mass (CT: 7/43[16%] vs. 2/80[2.5%], p = 0.009; MRI: 12/34[35%] vs. 8/68[12%], p = 0.008), necrosis (CT: 16/43[37%] vs. 14/80[18]%, p = 0.026), intralesional arteries (CT: 26/43[60%] vs. 32/80[40%], p = 0.038). A subgroup of 98 high risk patients (hepatitis B, morphologic cirrhosis) were assigned LI-RADS categorization; majority of patients were assigned LR-5 (CT: 15/25[60%] vs. 21/52[40%]; MRI: 10/18[56%] vs. 19/44[43%]). No feature was significantly associated with CTNNB1 mutation status after multiple testing adjustment. Conclusion Compared to wildtype, CTNNB1-mutated HCCs are more likely to appear as solitary masses with mosaic, heterogeneous appearance containing blood products, necrosis and intralesional arteries. Majority of CTNNB1-mutated tumors were categorized as LR-5 in a subgroup of high risk patients. No imaging feature independently predicted CTNNB1-mutated HCCs.


  • Reply to “Hepatic Adenomas With Hepatobiliary Phase Iso- or Hyperintensity: Standardized Definitions Are Required”

    by Tae-Hyung Kim, Sungmin Woo, Sanam Ebrahimzadeh, Matthew D. F. Mclnnes, Scott R. Gerst, Richard K. Do

  • Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid–Enhanced MRI: Systematic Review and Meta-Analysis

    by Tae-Hyung Kim, Sungmin Woo, Sanam Ebrahimzadeh, Matthew D. F. McInnes, Scott R. Gerst, Richard K. Do

    Background: Accumulating evidence indicates that hepatocellular adenoma (HCA) may have a higher frequency of hepatobiliary phase (HBP) iso- or hyperintensity than previously reported. Objective: To...